The Ewing Marion Kauffman Foundation was established by the late entrepreneur and philanthropist Ewing Marion Kauffman. The Kauffman Foundation focuses on developing entrepreneurship and improving the education of children and youth through entrepreneurship, advancing innovation, education, and research and policy. IAMI is supported by the Kauffman Foundation in an effort to improve the efficiency with which university technologies are advanced to the market.
IAMI is supported by the Kauffman Foundation in an effort to improve the efficiency with which university technologies are advanced to the market.
In the area of advancing innovation, our research suggests that many innovations residing in universities are slow getting to market, and many will never reach the market.
As we look to improve this complex task, we work to research the reasons why the system is not more productive, explore ways to partner with universities, philanthropists, and industry to ensure greater output, and ultimately foster higher levels of innovative entrepreneurship through the commercialization of university-based technologies. The result is more and better options for patients and their families.
The Leukemia & Lymphoma Society is the world's largest voluntary (nonprofit) health organization dedicated to funding blood cancer research and providing education and patient services. The partnership with IAMI and the University of Kansas has helped the Leukemia & Lymphoma Society and its collaborators deliver promising new treatments to patients in need.
The partnership with IAMI and the University of Kansas has helped the Leukemia & Lymphoma Society and its collaborators advance promising new treatments to patients in need.
The LLS Therapy Acceleration Program (TAP) exists to advance the diagnosis and treatment of blood cancers through continued funding of academic research, the therapy acceleration program and other special initiatives. Additionally, we proactively establish a research agenda and direct a portion of research spending to specific areas of unmet medical need for leukemia, lymphoma & myeloma.
TAP also participates directly in blood cancer therapy development by expanding research beyond academic collaborations and biotech partnerships to include pharmaceutical companies and/or venture capitalists.
The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the nation's medical research agency - making important discoveries that improve health and save lives. NIH is the largest source of funding for medical research in the world, creating hundreds of thousands of high-quality jobs by funding thousands of scientists in universities and research institutions. Together, the NIH Therapeutics for Rare and Neglected Diseases (TRND) program and IAMI are demonstrating a new way for government and academia to work together for a positive effect on patients' lives.
Together, the National Institutes of Health (NIH) Therapeutics for Rare and Neglected Diseases (TRND) program and IAMI are demonstrating a new way for government and academia to work together for a positive effect on patients' lives.
The TRND program is an effort to encourage and speed the development of new drugs for rare and neglected diseases.
This program is specifically intended to stimulate drug discovery and development research collaborations between NIH and academic scientists, nonprofit organizations, and pharmaceutical and biotechnology companies working on rare and neglected illnesses.
IAMI's approach is extremely complementary to the objectives of the program.
Children's Mercy Hospitals and Clinics is a comprehensive pediatric medical center providing state-of-the-art care for children from birth to age 18. Children's Mercy Kansas City is consistently ranked among the leading children's hospitals in the nation. Through partnerships with IAMI and the University of Kansas Cancer Center, Children's Mercy Kansas City has been able to advance a number of discoveries to the point that they become treatment options for patients.
Through partnerships with IAMI and the University of Kansas Cancer Center, Children's Mercy Kansas City has been able to advance a number of discoveries to the point that they become treatment options for patients.
Patient care is the core goal at Children's Mercy, but is it just one part of the tripartite institutional mission: to serve, to teach and to discover.
Children's Mercy actively embraces this mission recognizing that innovation in providing state-of-the-art patient care only comes by being dedicated to the process of discovery through the effective performance of relevant research and subsequently, translating new information into knowledge that is capable of driving critical therapeutic decisions and diagnostic interventions.
Through world-class research and patient care, The University of Kansas Cancer Center is working toward a world without cancer and ending the burden of cancer in the Heartland. Innovation and discovery are at the heart of academic medicine, so it is logical they drive the collaborative partnership between The University of Kansas Cancer Center and IAMI.
Innovation and discovery are at the heart of academic medicine, so it is logical they drive the collaborative partnership between The University of Kansas Cancer Center and IAMI.
Cancer is an insidious disease numbering more than 200 different types and variations. To defeat this beast, novel therapies must be created through revolutionary basic science research and ingenious drug formulations to stop cancer cells in their tracks.
It is our commitment to exactly this approach that places The University of Kansas Cancer Center at the vanguard of the war against cancer. The KUCC doctors and scientists collaborate on new and more effective drug and treatment therapies. Their goal is to prevent, treat and, ultimately, end cancer.
Patients benefit from a strong and unified team approach when it comes to facing cancer. The patient care team provides the most advanced care and the best possible service to patients.
KU Medical Center strives to educate exceptional health care professionals through a full range of undergraduate, graduate, professional, postdoctoral and continuing education programs. Biomedical research, a topic of intense interest throughout the nation, is the focus of a comprehensive plan to build on our many assets to place the university among the nation's top institutions of higher education.
Biomedical research, a topic of intense interest throughout the nation, is the focus of a comprehensive plan to build on our many assets to place the university among the nation's top institutions of higher education.
The University of Kansas Medical Center provides excellence in patient care, research, education and community engagement. The physicians provide care for patients and clinical opportunity to students and residents.
KU Medical Center research is a hub of world-class programs and innovations with experts driving the technology. The long-standing reputation at the KU Medical Center results in state-of-the-art patient care with one purpose, helping the patient.
Frontiers: University of Kansas Clinical and Translational Science Institute is a network of scientists from across the Kansas City region and the state of Kansas working on translational research - research that transforms laboratory discoveries into treatments and cures. IAMI works in partnership with, and as part of, Frontiers: The Heartland Institute for Clinical and Translational Research to accelerate the process by which laboratory discoveries become patient treatments.
IAMI works in partnership with, and as part of, Frontiers: University of Kansas Clinical and Translational Science Institute to accelerate the process by which laboratory discoveries become patient treatments.
To advance innovations in translational research, Frontiers encourages collaboration and resource sharing among a network of scientists and clinicians at academic institutions and health care systems across Kansas and the Kansas City metropolitan area. Frontiers investigators work collaboratively to speed the translation of laboratory discoveries into treatments for patients, to engage communities in clinical research efforts and to train a new generation of clinical and translational researchers.
To address the emerging issues of health care, Frontiers investigators work with leading institutions across the country and with communities to identify their health care needs.
The University of Kansas is a major public research and teaching institution that operates through a diverse, multicampus system. KU's many parts are bound together by a mission to serve as a "center for learning, research, scholarship and creative endeavor" in Kansas, the nation and the world.
The University of Kansas is the flagship university of the state of Kansas The university was opened in 1866, under a charter granted by the Kansas Legislature in 1864.
The University's Medical Center and Hospital are located in Kansas City, Kansas. The Edwards Campus is in Overland Park, Kansas in the Kansas City, Mo., metro area. There are also educational and research sites in Parsons and Topeka, and branches of the University of Kansas School of Medicine in Wichita and Salina.
KU Innovation and Collaboration is a 501(c)(3) jointly-controlled by the KU Center for Research and KU Medical Center Research Institute whose mission is to maximize the impact of university intellectual property to benefit the university and society.
KU has a strong tradition of effective technology transfer built on research in such fields as drug development and delivery; education and human development; biosciences, biofuels and bioengineering; information technologies and informatics; and remote sensing.
Also important is the education of students, faculty and the public about the economic importance of entrepreneurial activity.
The Bioscience & Technology Business Center in Lawrence, Kan., represents a unique partnership between local and state entities united to expand the local economy by promoting the local bioscience and technology industries. The center provides fundamental resources necessary to successfully grow startup companies and collaborations. The Bioscience & Technology Business Center has provided resources and space to move medical innovations quickly through the pipeline.
The Bioscience & Technology Business Center (BTBC) represents a unique partnership between local and state entities united to expand the local economy by promoting the local bioscience and technology industries.
The center combines three fundamental resources necessary to successfully grow startup companies and collaborations. They are a modern state-of-the-art wet lab facility comprised of wet lab, dry lab, and office space, offering superior amenities, access to KU resources and research expertise and capital raising and consulting services from successful, experienced incubator staff.
As an independent, nonprofit organization and the official fundraising foundation for the University of Kansas, KU Endowment partners with donors in providing philanthropic support to build a greater KU. An $8 million matching grant from KU Endowment helped launch IAMI in 2008. Since then, KU Endowment has supported IAMI's efforts to bring new drugs and medical treatment to the market.
Established in 1891 as America's first foundation for a public university, we embrace our responsibility to inspire philanthropy for KU, and we are committed to following the highest standards of service and ethical conduct when it comes to managing donors' gifts for the benefit of the university.
The support of donors helps make KU a world-class institution. State financing covers only about 21 percent of KU's total operating expenses. Therefore, private gifts play a major role in virtually all activities of the university.